Cell therapy for multiple system atrophy
Part of Brain & nervous system clinical trials.
This trial tests a new cell therapy given directly into the brain to see if it is safe and can help with symptoms of multiple system atrophy (MSA), a condition that affects movement and balance. It may offer a new way to slow or improve symptoms for people with this disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 75 years old.
- You have been diagnosed with multiple system atrophy (the Parkinson's type) and your movement symptoms started within the last 5 years.
- You do not have other brain conditions like Parkinson's disease, Lewy body dementia, or other serious neurological disorders.
- You are healthy enough for brain surgery and MRI/PET scans, with no major brain abnormalities.
- You do not have severe depression, anxiety, or dementia.
- You have no active infections like hepatitis, HIV, or syphilis, and no history of cancer (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
This trial tests whether a patient's own stem cells can help treat multiple system atrophy, a rare condition that affects movement and balance. The therapy may help slow or improve symptoms.
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
Hear when a new the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.